During Q4 2018 the big money sentiment decreased to 1.27. That’s change of 0.40, from 2018Q3’s 1.67. 31 investors sold all, 47 reduced holdings as Immunomedics, Inc. ratio is negative. 63 increased stakes while 36 funds bought stakes. Funds hold 148.22 million shares thus 6.95% more from 2018Q3’s 138.59 million shares.
2,750 were accumulated by Sandy Spring Comml Bank. Credit Suisse Ag holds 0% in Immunomedics, Inc. (NASDAQ:IMMU) or 109,589 shs. State Of Wisconsin Investment Board stated it has 146,600 shs or 0.01% of all its holdings. Amer Century Incorporated owns 0.05% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 3.12 million shs. Moreover, Balyasny Asset Mgmt Lc has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 11,520 shs. 11,031 are held by Quantitative Systematic Strategies Ltd Co. Moody Fincl Bank Tru Division reported 288 shs. Polar Capital Llp has 0.14% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 904,416 shs. Illinois-based Rmb Capital Management Ltd Liability Corporation has invested 0.02% in Immunomedics, Inc. (NASDAQ:IMMU). Thrivent Fincl For Lutherans has invested 0.01% in Immunomedics, Inc. (NASDAQ:IMMU). Ghost Tree Cap Limited Liability Company holds 4% or 800,000 shs. Ubs Asset Management Americas stated it has 726,958 shs. Moreover, Franklin Resources Inc has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 775,886 shs. New York-based Mackay Shields Llc has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Bradley Foster Sargent Inc Ct holds 0.01% or 14,000 shs.

Immunomedics, Inc. (NASDAQ:IMMU) declined significantly to $18.03. On Apr, 1 it was reported by Barchart.com. Immunomedics, Inc. (NASDAQ:IMMU) has $3.44 billion MC. At $17.49 stock target, the company valuation changes by $103.32M less.

Immunomedics, Inc. (NASDAQ:IMMU)’s quarterly earnings will be published on May, 8., according to Zacks. Analysts predict $-0.35 EPS, which is $0.21 down or 150.00 % from 2018’s $-0.14 EPS. Analysts at Wall Street see Immunomedics, Inc.’s -30.00 % EPS growth compared to $-0.50 EPS for last quarter.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

In total 8 analysts cover Immunomedics (NASDAQ:IMMU). “Buy” rating has 7, “Sell” are 0, while 1 are “Hold”. (NASDAQ:IMMU) has 88% bullish analysts. 11 are the (NASDAQ:IMMU)’s ratings reports on Apr 1, 2019 according to StockzIntelligence Inc. On Monday, March 11 the rating was maintained by Cowen & Co with “Buy”. On Monday, March 4 the firm earned “Buy” rating by Canaccord Genuity. In Monday, February 25 report Piper Jaffray maintained it with “Buy” rating and $20 target. On Tuesday, January 22 Morgan Stanley downgraded Immunomedics, Inc. (NASDAQ:IMMU) rating. Morgan Stanley has “Equal-Weight” rating and $17 target. On Thursday, November 8 Jefferies reinitiated Immunomedics, Inc. (NASDAQ:IMMU) rating. Jefferies has “Buy” rating and $30 target. On Tuesday, February 26 the rating was maintained by FBR Capital with “Buy”. On Friday, January 18 the stock has “Market Perform” rating by Wells Fargo.

A couple more Immunomedics, Inc. (NASDAQ:IMMU) news were brought out by: Globenewswire.com which released on March 04, 2019 “Immunomedics to Participate in Cowen and Company 39th Annual Health Care Conference – GlobeNewswire”, also Nasdaq.com on March 07, 2019 brought out “Surprising Analyst 12-Month Target For IYY – Nasdaq”, the next Globenewswire.com is “Immunomedics Appoints Barbara G. Duncan to Board of Directors – GlobeNewswire” on March 07, 2019. Nasdaq.com has article titled “Notable ETF Outflow Detected – XBI, LGND, IMMU, NBIX – Nasdaq”.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases.The company has $3.44 billion market cap. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.Last it reported negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.